Safety Reading Notes

Read safety context beside the research guide.

The TRPV4 cannabinoid target source set should still be read with safety context in mind. Mechanistic or preclinical evidence should not be converted into consumer instructions, and product identity can change how closely a source applies. PMID 33629929

PubMed For Dummies Article

TRPV4 cannabinoid target Evidence Review: the long-form source walk-through

Quick read
  • TRPV4 cannabinoid target currently has 14 source-backed evidence row(s), so this page should be read as a research guide rather than a single conclusion. PMID 33629929
  • The evidence classes most visible in the row language are mechanistic or pharmacological (8), and insufficient (6). PMID 30697147
  • The study-design language most visible in the row language is Narrative or expert review (5), Animal study (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 33362478
  • The repeated topics are TRPV4 (14), which tells the reader where to start opening PubMed and DOI links. PMID 21726418

Start with the research question

TRPV4 cannabinoid target is built from 14 source-backed evidence row(s) and 14 research source(s). The current evidence classes read as mechanistic or pharmacological (8), and insufficient (6), and the study-design language most often reads as Narrative or expert review (5), Animal study (5), Cellular or in vitro study (2), and other mapped categories (1). PMID 33629929

The row-level question is not simply whether TRPV4 cannabinoid target is "good" or "bad." The useful question is what each row studied, what evidence class it received, and whether the source is close to the reader's actual question. The most repeated row topics are TRPV4 (14). PMID 30697147

Human evidence 0 rows

Rows involving human participants, patients, or clinical source language. These rows are closer to everyday reader questions, but still depend on population, dose, route, comparator, and endpoint. PMID 19070372

Preclinical evidence 0 rows

Animal, cellular, or model-based rows. These can explain why a topic is being studied, but they should not be read as human-health instructions. PMID 28945920

Mechanistic evidence 8 rows

Rows about receptors, enzymes, channels, metabolism, binding, signaling, or pharmacology. These explain plausibility without proving a consumer outcome. PMID 32051870

Limits and uncertainty 6 rows

Rows where safety, tolerability, risk, product limits, or insufficient evidence need to stay visible next to the rest of the article. PMID 38750093

The lane labels are not a quality score. They are a reading method: keep human evidence, preclinical evidence, mechanisms, and uncertainty in separate mental boxes before deciding what a source can actually support. PMID 29470146

Where this page has the most source density

The largest bucket surfaced for this page is TRPV4: mechanistic or pharmacological. That does not automatically mean the topic is settled; it means this is where the current source trail is densest. The next visible bucket is TRPV4: insufficient, which gives readers another way to see what the literature repeatedly circles. PMID 33629929

Source density should be read with evidence posture. A bucket can contain many rows and still be limited if the studies are indirect, mixed, preclinical, product-specific, or mostly review-level. The paragraphs below name the buckets directly and keep each explanation connected to a source record. PMID 30697147

Bucket chapters: what the literature is circling

TRPV4: mechanistic or pharmacological

8 research sources 8 rows (1018-1028) Evidence class: mechanistic or pharmacological

This bucket summarizes source-backed rows focused on TRPV4: mechanistic or pharmacological. It currently draws from 8 research source(s), so the exact study type matters. PMID 33629929

Read this bucket as mechanism or pharmacology context. Mechanisms can make the biology easier to understand, but they are not the same thing as a demonstrated effect in people. PMID 33629929

  • Evidence row 1018

    CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pha... PMID 33629929

  • Evidence row 1028

    CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, sig... PMID 25061872

TRPV4: insufficient

6 research sources 6 rows (1016, 1017, 1020, 1024, 1025, 1029) Evidence class: insufficient

This bucket summarizes source-backed rows focused on TRPV4: insufficient. It currently draws from 6 research source(s), so the exact study type matters. PMID 30697147

Read this bucket as an uncertainty marker. The source trail exists, but the current evidence posture is not strong enough for a broad plain-English conclusion. PMID 30697147

  • Evidence row 1016

    THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147

  • Evidence row 1017

    CBD modulates TRPV4; evidence class: insufficient (outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 33362478

Human evidence, mechanisms, and safety are different lanes

This page currently separates human evidence (0 row(s)), mechanistic evidence (8 row(s)), and safety/tolerability context (0 row(s)). That separation is the heart of the site. Mechanistic evidence can make a topic biologically interesting, but it should not silently become a human outcome. PMID 33629929

Human evidence still depends on population, dose, route, duration, product identity, and endpoint. Safety rows belong in the same reading path as benefit-oriented rows because formulation, co-exposures, prescription medications, impairment context, and higher-risk populations can change how close a source is to a reader's question. PMID 30697147

What this does and does not mean

  • It means the page has a traceable source trail. It does not mean every bucket has the same clinical strength. PMID 26990140
  • It means mechanisms, animal models, human studies, safety rows, and insufficient-evidence rows are being kept visible as separate evidence types. PMID 41802611
  • It does not turn a preclinical mechanism into a consumer recommendation, and it does not treat one product, dose, route, or population as interchangeable with another. PMID 26294342

How to use the source table

The source-backed evidence table below is the audit trail. Each row keeps a public sentence connected to a source record when a PubMed ID or DOI is available. If a sentence feels important, the reader should be able to click through, inspect the study type, and decide whether the source is close to the question they care about. PMID 33629929

This is why the public page is intentionally layered. The top gives the reader a fast orientation. The bucket table groups repeated rows into readable topics. The article body explains the buckets using the actual evidence-row language. The source notes below walk through every evidence row before the source table repeats the technical trace. PMID 30697147

Source-reading checklist for TRPV4 cannabinoid target

  1. Open the linked PubMed or DOI record. PMID 25061872
  2. Check whether the source studied humans, animals, cells, chemistry, pharmacology, product testing, or a review of prior literature. PMID 40006844
  3. Compare the source product, dose, route, population, and endpoint to the question being asked. PMID 33629929
  4. Look for safety, tolerability, drug-interaction, impairment, pregnancy, pediatric, psychiatric, cardiovascular, and product-quality context before treating the bucket as settled. PMID 30697147
  5. Return to the evidence table when the article summary sounds too broad; the row is the audit unit. PMID 33362478

Source Notes

TRPV4 cannabinoid target source-by-source reading notes

These notes pull every evidence row on this page into the readable article body before the source table repeats the audit trail. Each note keeps the row language beside the PubMed or DOI link when available.

  1. Evidence row 1016

    THC modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 30697147

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Cannabinoid Ligands Targeting TRP Channels.
  2. Evidence row 1017

    CBD modulates TRPV4; evidence class: insufficient (outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 33362478

    Evidence class: insufficient. Source: An Analysis of the Putative CBD Binding Site in the Ionotropic Cannabinoid Receptors.
  3. Evidence row 1018

    CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 33629929

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabidiol inhibits human glioma by induction of lethal mitophagy through activating TRPV4.
  4. Evidence row 1019

    THC modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 21726418

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Cannabinoid actions at TRPV channels: effects on TRPV3 and TRPV4 and their potential relevance to gastrointestinal inflammation.
  5. Evidence row 1020

    Cannabinoids modulates TRPV4; evidence class: insufficient (study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 19070372

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Role of ionotropic cannabinoid receptors in peripheral antinociception and antihyperalgesia.
  6. Evidence row 1021

    CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 28945920

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Human podocytes express functional thermosensitive TRPV channels.
  7. Evidence row 1022

    Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 32051870

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Modification of TRPV4 activity by acetaminophen.
  8. Evidence row 1023

    Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Human clinical study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 38750093

    Evidence class: mechanistic or pharmacological; Study design: Human clinical study. Source: Transcriptomic signature, bioactivity and safety of a non-hepatotoxic analgesic generating AM404 in the midbrain PAG region.
  9. Evidence row 1024

    Cannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 29470146

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Toward an effective peripheral visceral analgesic: responding to the national opioid crisis.
  10. Evidence row 1025

    Endocannabinoids modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26990140

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Potential Future Pharmacological Treatment of Bladder Dysfunction.
  11. Evidence row 1026

    Cannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Animal model mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 41802611

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Peripheral cannabinoid receptor activation attenuates frostbite-induced chronic pain via modulation of TRP channels, neuroinflammation, and autophagy.
  12. Evidence row 1027

    Endocannabinoids modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Animal study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 26294342

    Evidence class: mechanistic or pharmacological; Study design: Animal study. Source: Role of endothelial TRPV4 channels in vascular actions of the endocannabinoid, 2-arachidonoylglycerol.
  13. Evidence row 1028

    CBD modulates TRPV4; evidence class: mechanistic or pharmacological (population or model: Human participants or patients mentioned; study design: Cellular or in vitro study; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 25061872

    Evidence class: mechanistic or pharmacological; Study design: Cellular or in vitro study. Source: Cannabidiol exerts sebostatic and antiinflammatory effects on human sebocytes.
  14. Evidence row 1029

    CBD modulates TRPV4; evidence class: insufficient (population or model: Human participants or patients mentioned; study design: Narrative or expert review; outcome measure: TRPV4 channel activity, binding, signaling, or pharmacology). PMID 40006844

    Evidence class: insufficient; Study design: Narrative or expert review. Source: Mechanisms of Cell Death Induced by Cannabidiol Against Tumor Cells: A Review of Preclinical Studies.